The Korea Herald

[Herald Interview] Carbon-neutral Philips sets higher goals for 2025

IndustryMar 1, 2021

For anyone who has tried, it is evident that reducing one’s carbon footprint requires an extraordinary attention to the waste produced, coupled with a conscious effort to cut down on convenient habit...
GC WellBeing to repurpose liver drug as COVID-19 treatment

IndustryFeb 26, 2021

GC WellBeing will conduct a phase 2 clinical trial of its liver drug Laennec, to repurpose it as a COVID-19 treatment, the Ministry of Food and Drug Safety said Friday. This puts the total count of ...
Pfizer vaccine approval in Korea imminent, FDA allows more flexible storage

IndustryFeb 26, 2021

South Korea on Friday paved the way to approving Pfizer’s mRNA vaccine for COVID-19 as another group of pharmaceutical experts positively opined on the vaccine’s efficacy and safety. On the same day...
EMA starts rolling review of Celltrion’s COVID-19 treatment

IndustryFeb 25, 2021

European Medicines Agency said Wednesday, local time, that it has started a “rolling review” of data on South Korean company Celltrion’s monoclonal antibody regdanvimab. Regdanvimab, also known as C...
Christopher Ko shares visions as Bio association representative

IndustryFeb 24, 2021

South Korean biosimilar maker Samsung Bioepis’ CEO Christopher Ko on Wednesday carried out his first public event as the new chairperson of the Korea Bio Association. Korea Bio is an association rep...
Elekta’s next-gen MRI device offers new hope for cancer patients

IndustryFeb 24, 2021

Swedish medical device company Elekta wants to give renewed hopes to cancer patients through its next-generation radiotherapy device Unity. Elekta on Wednesday launched Unity in Korea, making it the...
Korean experts advise Pfizer vaccine for 16 and older

IndustryFeb 23, 2021

The first of the three-part evaluation of Pfizer’s COVID-19 vaccine here has shown the vaccine to be 95 percent effective and eligible for use on those aged 16 and older, South Korea’s Drug Ministry ...
[Herald Interview] Software dons role of therapeutics

IndustryFeb 22, 2021

When talking about medical devices, conventional hardware with analytical or therapeutic functions for human health usually come to mind. But computer software that seeks to cure or alleviate sympto...
Macrogen, Lifex Biolabs to research Parkinson’s treatment

IndustryFeb 22, 2021

Precision life science company Macrogen will collaborate with US-based Lifex Biolabs on Parkinson’s disease treatment research, Macrogen announced Monday. This is a follow-up to Macrogen’s strategic...
Samsung Display joins responsible business alliance

IndustryFeb 21, 2021

Samsung Display’s chief executive officer Choi Joo-sun is aiming to further embolden the company’s environmental, social and governance (ESG) involvement beginning this year. As part of this drive, ...
Celltrion to take on S. Africa variant

IndustryFeb 18, 2021

Only a day after Celltrion began distribution of its monoclonal antibody therapy for COVID-19 in Korea, the company announced Thursday that it is setting out to tackle the more contagious South Afric...
Celltrion begins distribution of COVID-19 therapy in Korea

IndustryFeb 17, 2021

Celltrion began nationwide distribution of its monoclonal antibody therapy for COVID-19 on Wednesday. Celltrion’s regdanvimab is Korea’s first emergency-approved COVID-19 treatment. All 156 state-d...
[News Focus] More homegrown COVID-19 therapies coming

IndustryFeb 16, 2021

Following Celltrion’s monoclonal antibody treatment for COVID-19, a slew of homegrown therapies is on the way in the first half of 2021. Chong Kun Dang Pharmaceutical is set to submit application fo...
SK Bioscience to manufacture Novavax vaccine for 20 mil population

IndustryFeb 16, 2021

South Korean vaccine-maker SK Bioscience will manufacture 40 million doses of US’ Novavax vaccines, enough to inoculate 20 million people. Under the agreement signed by SK Bioscience, Korea Disease ...
Celltrion’s Humira biosimilar gains European sales approval

IndustryFeb 15, 2021

Celltrion’s Yuflyma, an adalimumab biosimilar for autoimmune diseases, has been given the green light by the European Commission on Feb. 11, allowing for it to be sold in the European market, Celltri...